MacuHealth Announces Canadian Medical Advisory Board
BIRMINGHAM, Mich., Oct. 1, 2018 /CNW/ -- MacuHealth is honoured to introduce its Medical Advisory Board to the Eye Care Professionals of Canada and continue to uphold its tradition of excellence in science and products. The board is comprised of premier retina specialists, experts, and key opinion leaders in ophthalmology across Canada. The newly appointed advisory board will provide MacuHealth with valuable insight to help shape the company's overall nutraceutical direction in supporting patients with a lifetime of superior eye health and exceptional vision. From its original 3 Senior Members, Dr. Alan Berger, BSc., MDCM, FRCSC, Dip. ABO, Dr. Robert Devenyi, MD, MBA, FRCSC, FACS., and Dr. Jeffrey Machat, MD, FRCSC, DABO., the board will soon expand to provide representation at the Provincial level in order to provide all eye-care-professionals with the state-of-the art science and information on MacuHealth.
"We are extremely honoured to present our Canadian Medical Advisory Board," says MacuHealth President and CEO Frédéric Jouhet. "MacuHealth has a strong position in Canada and is committed in supporting all eye-care professionals in delivering the utmost science-based care to their patients. Having a prestigious group of doctors on our Board helps us provide the best product for Macular Degeneration patients and overall visual performance, this is a tremendous opportunity to reach all doctors and patients."
Currently, MacuHealth offers two products:
MacuHealth® with LMZ3 is the only dietary supplement containing all three critical nutrients, Lutein, Meso-Zeaxanthin and Zeaxanthin in a 10:10:2 ratio that makes up macular pigment. Taken once a day, this small, easy-to-swallow soft gel is clinically proven to restore macular pigments to normal levels, resulting in enhanced vision and aid in the prevention of age-related macular degeneration.
MacuHealth PLUS+ is the AREDS2* formulation, with two important distinctions. Firstly, Zinc is reduced from 80mg to 25mg, thereby compliant with recommended dietary allowance and addressing the possibility of any increased risk for disease progression in AMD patients with a particular genetic background. Secondly, the addition of 10mg of Meso-Zeaxanthin (the third most potent and centrally dominant macular carotenoid) thereby facilitating maximum augmentation of macular pigment and facilitating optimization of visual performance in eyes with AMD.
Medical Advisory Board:
Robert G. Devenyi, MD, MBA, FRCSC, FACS.
Dr. Devenyi is a vitreoretinal surgeon and Professor of Ophthalmology and Vision Sciences at the University of Toronto. He is Ophthalmologist-in-Chief and Director of Retinal Services at the University Health Network, which is affiliated with the University of Toronto. He is also the Co-Director of the Donald K. Johnson Eye Institute located at the Toronto Western Hospital, part of UHN. The DKJ Eye Institute is Canada's premier subspecialty ophthalmology facility. Dr. Devenyi is also the team ophthalmologist for the Toronto Maple Leafs of the National Hockey League.
Alan Richard Berger, BSc., MDCM, FRCSC, Dip. ABO
Dr. Berger is the Clinical Vice Chairman for Ophthalmology and Vision Sciences at the University of Toronto and is also the Co-Chairman of the Toronto Central LHIN Vision Strategy Task Force. He was Ophthalmologist-in-Chief at St. Michael's Hospital from 2002 until 2014. He was also the President of the Medical Staff Association of St. Michael's Hospital from 2008 to 2010 and was Vice President and one of the founding members of the Toronto Ophthalmological Society. Dr. Berger has authored over 40 peer-reviewed scientific journal articles and has written 7 book chapters. He has given over 275 lectures and presentations at local, national and international meetings.
Jeffery Machat, MD, FRCSC, DABO
Dr. Machat co-founded and developed the largest laser vison correction company in the world, TLC Laser Eye Centers, with 83 fixed site clinics across North America, as well as 300 mobile sites. Currently, he is the Founder and Medical Director of Crystal Clear Vision, a state-of-the-art facility in downtown Toronto. Dr. Machat was one of the first handful of surgeons in North America to perform LASIK and other laser refractive surgery techniques thus lecturing and training surgeons in 24 countries. He has performed over 70,000 laser vision correction procedures over his 26-year career.
About MacuHealth®:
Founded in 2006, MacuHealth® with LMZ3 formula contains 10 mg of Lutein, 2 mg of Zeaxanthin and 10 mg of the most potent antioxidant in the macula, Meso-Zeaxanthin. MacuHealth takes immense pride in having helped to pioneer much of the revolutionary research behind the critical carotenoid, Meso-Zeaxanthin and its role in preserving and improving visual function. More recently, the company has been supporting the emerging research on the fascinating correlation between carotenoid levels, impaired vision and cognitive performance. With over 30 peer reviewed publications that demonstrate the formula's efficacy, bioavailability and safety, plus a passion for protecting eyesight, MacuHealth® is at the forefront of preventative treatments for macular disease. The company holds both worldwide exclusivity and a patent on the science-based 10-10-2 formulation. With help from its distribution groups, MacuHealth in North America and MacuHealth World, it has become the supplement of choice in the fight against AMD and enhancement of visual function worldwide.
For more information please visit www.MacuHealth.com
SOURCE MacuHealth
Milka Sabourin, [email protected]
Share this article